American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy.

Area of Science:

• Oncology
• Radiation Oncology
• Surgical Oncology

Background:

• Radiation therapy is increasingly recognized for its role in treating soft tissue sarcoma (STS).
• Brachytherapy has a long history in STS management, used alone or as a radiation boost.
• The American Brachytherapy Society provides updated clinical practice guidelines for STS brachytherapy.

Purpose of the Study:

• To present updated guidelines on brachytherapy utilization in soft tissue sarcoma management.
• To offer clinicians data on indications and performance of STS brachytherapy.
• To ensure safe delivery of high-quality STS brachytherapy with minimal toxicity.

Main Methods:

• Development of updated clinical practice guidelines by American Brachytherapy Society members.
• Guideline creation based on a comprehensive literature review and clinical expertise in STS brachytherapy.
• Inclusion of step-by-step procedural details for performing STS brachytherapy.

Main Results:

• Brachytherapy monotherapy is recommended for lower-recurrence risk STS or post-external beam radiation recurrence.
• A brachytherapy boost is suitable for higher-risk patients meeting specific implant criteria.
• Dose/fractionation regimens vary by tumor site and intent; wound complication management involves closure techniques and timing.

Conclusions:

• These guidelines offer crucial data for STS brachytherapy indications.
• Clinicians are provided with methods for safe and effective STS brachytherapy delivery.
• The guidelines aim to minimize treatment-related toxicity in soft tissue sarcoma patients.